This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Cerebrolysin
A peptide preparation derived from porcine brain tissue containing neurotrophic factors similar to NGF, BDNF, and CNTF - administered by injection and widely used across Eastern Europe, Russia, and China for stroke recovery, traumatic brain injury, Alzheimer's disease, and vascular dementia.
Benefits
What is Cerebrolysin?
Cerebrolysin is a unique neuropeptide preparation produced by the standardised enzymatic proteolysis of lipid-free porcine brain tissue. Manufactured by the Austrian pharmaceutical company EVER Neuro Pharma (formerly Ebewe), each millilitre of Cerebrolysin contains approximately 15% low-molecular-weight neuropeptides (below 10 kDa) and 85% free amino acids. The peptide fraction contains sequences functionally analogous to endogenous neurotrophic factors including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), and glial cell line-derived neurotrophic factor (GDNF). This multi-target neurotrophic activity distinguishes Cerebrolysin from single-molecule pharmaceuticals.
Cerebrolysin has been the subject of over 200 clinical studies involving more than 70,000 patients worldwide. A Cochrane systematic review by Chen et al. (2012) examined the evidence for Cerebrolysin in vascular dementia, finding "some evidence" of beneficial effects on global clinical assessment. A 2013 meta-analysis by Gauthier et al. published in Drugs and Aging pooled data from six randomised controlled trials involving 819 Alzheimer's patients, finding significant improvements in global clinical function (CIBIC+) and cognitive performance (ADAS-cog) with 30 mL daily infusions over 4 weeks. The CASTA trial (Cerebrolysin and Recovery After Stroke), published in Stroke (2012), demonstrated improved motor recovery in acute ischaemic stroke patients. Despite this substantial evidence base, Cerebrolysin remains unapproved by the FDA and is primarily used clinically in Russia, China, Eastern Europe, and parts of Asia and Latin America.
- Neurotrophic factor mimicry: The neuropeptide fraction contains sequences that activate the same receptor systems as endogenous BDNF, NGF, and CNTF, promoting neuronal survival, axonal growth, and synaptic plasticity without the blood-brain barrier penetration issues of full-length neurotrophins
- Neuroprotection: Reduces glutamate excitotoxicity, inhibits calpain-mediated cell death, and stabilises intracellular calcium levels during ischaemic and traumatic brain injury, limiting the extent of secondary neuronal damage
- Neurogenesis stimulation: Promotes proliferation and differentiation of neural stem cells in the subventricular zone and hippocampal dentate gyrus, supporting the brain's endogenous repair mechanisms
- Synaptic repair: Enhances synaptophysin expression and increases dendritic branching complexity, restoring synaptic architecture damaged by neurodegeneration, stroke, or traumatic injury
- Anti-inflammatory effects: Reduces microglial activation and suppresses production of pro-inflammatory cytokines including TNF-alpha and IL-1beta, attenuating neuroinflammation that exacerbates cognitive decline
- Cognitive enhancement (off-label): 5 mL by intramuscular injection daily for 10-20 days, repeated in cycles every 3-6 months
- Alzheimer's disease (clinical): 30 mL by intravenous infusion (diluted in saline) daily for 20 consecutive weekdays, with treatment courses repeated every 3-6 months
- Stroke recovery: 30-50 mL by IV infusion daily, initiated within 72 hours of acute ischaemic stroke and continued for 10-21 days
- Traumatic brain injury: 10-30 mL by IV infusion daily for 10-20 days, depending on injury severity
- Administration: Must be administered by injection only (intramuscular for volumes up to 5 mL, intravenous infusion for larger volumes). Not orally bioavailable
- Injection-only administration: The requirement for IM or IV injection significantly limits accessibility and introduces risks inherent to parenteral drug administration including infection, phlebitis, and injection site reactions
- Common side effects: Dizziness, headache, sweating, and feeling of heat during IV infusion are the most frequently reported adverse effects. These are generally mild and transient
- Allergic reactions: Rare hypersensitivity reactions including skin rash and anaphylaxis have been reported. A test dose may be administered before the first full injection in sensitive individuals
- Contraindications: Not recommended in patients with epilepsy (may lower seizure threshold), severe renal impairment, or known allergy to porcine-derived products
- Regulatory status: Approved for clinical use in over 40 countries. Not FDA-approved in the United States. Available by prescription in Russia, China, and most of Eastern Europe
Natural Sources & Forms
- EVER Neuro Pharma: The sole manufacturer, producing Cerebrolysin as a sterile aqueous solution in 1 mL, 5 mL, 10 mL, and 30 mL ampoules
- International pharmacies: Available by prescription from pharmacies in Russia, China, and approved countries. Can sometimes be sourced through international pharmacy services
- Medical tourism: Some individuals travel to countries where Cerebrolysin is available to receive treatment cycles under medical supervision
- Cortexin (related product): A similar but distinct peptide preparation from bovine brain cortex, sometimes used as an alternative in countries where it is available
Frequently Asked Questions
A peptide preparation derived from porcine brain tissue containing neurotrophic factors similar to NGF, BDNF, and CNTF - administered by injection and widely used across Eastern Europe, Russia, and China for stroke recovery, traumatic brain injury, Alzheimer's disease, and vascular dementia.
The key benefits of Cerebrolysin include: Cognitive Enhancement, Creativity, Focus, Longevity, Memory, Mood.
Neurotrophic factor mimicry: The neuropeptide fraction contains sequences that activate the same receptor systems as endogenous BDNF, NGF, and CNTF, promoting neuronal survival, axonal growth, and synaptic plasticity without the blood-brain barrier penetration issues of full-length neurotrophins Neuroprotection: Reduces glutamate excitotoxicity, inhibits calpain-mediated cell death, and stabilises intracellular calcium levels during ischaemic and traumatic brain injury, limiting the extent of secondary neuronal damage Neurogenesis stimulation: Promotes proliferation and differentiation of neural stem cells in the subventricular zone and hippocampal dentate gyrus, supporting the brain's endogenous repair mechanisms Synaptic repair: Enhances synaptophysin expression and increases dendritic branching complexity, restoring synaptic architecture damaged by neurodegeneration, stroke, or traumatic injury Anti-inflammatory effects: Reduces microglial activation and suppresses production of pro-inflammatory cytokines including TNF-alpha and IL-1beta, attenuating neuroinflammation that exacerbates cognitive decline
Cognitive enhancement (off-label): 5 mL by intramuscular injection daily for 10-20 days, repeated in cycles every 3-6 months Alzheimer's disease (clinical): 30 mL by intravenous infusion (diluted in saline) daily for 20 consecutive weekdays, with treatment courses repeated every 3-6 months Stroke recovery: 30-50 mL by IV infusion daily, initiated within 72 hours of acute ischaemic stroke and continued for 10-21 days Traumatic brain injury: 10-30 mL by IV infusion daily for 10-20 days, depending on injury severity Administration: Must be administered by injection only (intramuscular for volumes up to 5 mL, intravenous infusion for larger volumes). Not orally bioavailable
Injection-only administration: The requirement for IM or IV injection significantly limits accessibility and introduces risks inherent to parenteral drug administration including infection, phlebitis, and injection site reactions Common side effects: Dizziness, headache, sweating, and feeling of heat during IV infusion are the most frequently reported adverse effects. These are generally mild and transient Allergic reactions: Rare hypersensitivity reactions including skin rash and anaphylaxis have been reported. A test dose may be administered before the first full injection in sensitive individuals Contraindications: Not recommended in patients with epilepsy (may lower seizure threshold), severe renal impairment, or known allergy to porcine-derived products Regulatory status: Approved for clinical use in over 40 countries. Not FDA-approved in the United States. Available by prescription in Russia, China, and most of Eastern Europe
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!